Page 175 - 2020_11-Haematologica-web

Letters to the Editor
References
1. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17.
2. WeiAH,StricklandSA,Jr.,HouJZ,etal.Venetoclaxcombinedwith low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277-1284.
3. GanzelC,SunZ,CripeLD,etal.Verypoorlong-termsurvivalinpast and more recent studies for relapsed AML patients: The ECOG- ACRIN experience. Am J Hematol. 2018;93(8):1074-1081.
4. DohnerH,EsteyE,GrimwadeD,etal.Diagnosisandmanagement of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.
5. Goldberg AD, Horvat TZ, Hsu M, et al. Venetoclax combined with either a hypomethylating agent or low-dose cytarabine shows activ- ity in relapsed and refractory myeloid malignancies. Blood. 2017; 130(Supplement 1):1353.
6. DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malig- nancies. Am J Hematol. 2018;93(3):401-407.
7. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological cor- relates of response in a phase II Study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discovery. 2016; 6(10):1106-1117.
8. Huemer F, Melchardt T, Jansko B, et al. Durable remissions with venetoclax monotherapy in secondary AML refractory to
hypomethylating agents and high expression of BCL-2 and/or BIM.
Eur J Haematol. 2019;102(5):437-441.
9. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommenda-
tions of the International Working Group for diagnosis, standardiza- tion of responsecCriteria, treatment outcomes, and reporting stan- dards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642-4649.
10. Ram R, Amit O, Zuckerman T, et al. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study. Ann Hematol. 2019; 98(8):1927-1932.
11. AldossI,YangD,PillaiR,etal.Associationofleukemiageneticswith response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Am J Hematol. 2019; 94(10):E253-E255.
12. Shahswar R, Hamwi I, Lueck C, et al. Registry for the off-label use of venetoclax in patients with relapsed or refractory acute myeloid leukemia. HemaSphere. 2018;2(Supplement 2):794.
13. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377-384.
14. Stahl M, DeVeaux M, Montesinos P, et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2(8):923-932.
15. Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012;30(20):2492-2499.
haematologica | 2020; 105(11)
2663